Citations 1
Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry
Abonour, Rafat , Rifkin, Robert M. , Gasparetto, Cristina , Toomey, Kathleen, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Ailawadhi, Sikander , Omel, James, Srinivasan, Shankar , Kitali, Amani, Agarwal, Amit , Investigators, the CONNECT MM Registry, Terebelo, Howard R , Ailawadhi, Sikander , Hardin, James W. , Jagannath, Sundar , Lee, Hans C. , Wagner, Lynne I. , Investigators, the CONNECT MM Registry
British Journal of Haematology | October 29, 2020 | Volume: 193 | Issue: 1 | Pages: 93-100
SummaryAlthough new multiple myeloma (MM) therapies are effective in alleviating some disease‐associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health‐related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide‐bortezomib‐dexamethasone [RVd (n = 445)], bortezomib‐melphalan‐prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy‐Multiple Myeloma subscale, EuroQol‐5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real‐world, largely community‐based population of patients with NDMM.